Filing Flows › Travere Therapeutics (TVTX) › Q3 2026 › vs Q2 2026
Travere Therapeutics (TVTX) Q3 2026 vs Q2 2026 (quarter over quarter)
Travere Therapeutics's revenue rose $55.0M (+32%) from $170M in Q2 2026 to $225M in Q3 2026. The biggest changes: Total net product sales +$58.8M (+36%); License and collaboration revenue −$3.9M (-47%).
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| FILSPARI | $200M | $141M | $59.1M | +42% |
| Tiopronin products | $20.0M | $20.3M | −$270K | -1% |
| Total net product sales | $220M | $161M | $58.8M | +36% |
| License and collaboration revenue | $4.4M | $8.2M | −$3.9M | -47% |
| Revenue | $225M | $170M | $55.0M | +32% |
| Other income, net | $9.9M | −$39.0M | $48.8M | — |
| Income tax benefit | $5.9M | $204K | $5.7M | 29× |
| Net loss | $52.3M | $34.8M | $17.5M | +50% |
| Costs & expenses | $293M | $205M | $88.1M | +43% |
| Operating costs | $293M | $166M | $127M | +77% |
| Cost of revenue | $2.9M | $2.2M | $693K | +32% |
| Research & development | $70.3M | $60.3M | $10.0M | +17% |
| SG&A | $98.4M | $96.1M | $2.3M | +2% |
| Other operating costs | $121M | $7.1M | $114M | 17× |
| Operating cash sources | $151M | $92.9M | $57.7M | +62% |
| Depreciation & amortization | $5.2M | $4.2M | $965K | +23% |
| Share-based compensation | $23.4M | $21.8M | $1.6M | +8% |
| Working capital & other | $122M | $66.8M | $55.1M | +82% |
| Net loss absorbed | $52.3M | $34.8M | $17.5M | +50% |
| Operating cash flow | $98.2M | $58.1M | $40.1M | +69% |
Questions
How much did Travere Therapeutics's revenue grow quarter over quarter in Q3 2026?
Travere Therapeutics's revenue rose $55.0M (+32%) from $170M in Q2 2026 to $225M in Q3 2026.
What drove Travere Therapeutics's revenue change in Q3 2026?
Total net product sales +$58.8M (+36%); License and collaboration revenue −$3.9M (-47%).